Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Hoth options GWU's aprepitant patents for dermatological side effects of erlotinib
29 Aug 2019
Following a sponsored research agreement announced last month, Hoth Therapeutics Inc. signed a definitive agreement with George Washington University, gaining an exclusive option to the latter's patents (Nos. 9,474,761 and 9,687,493) related to methods of using aprepitant or other neurokinin-1 (NK-1) receptor antagonists for topical and/or systemic therapy to address dermatological-related side effects of erlotinib in cancer patients.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?